曲奥舒凡暴露预测重型β地中海贫血患者无地贫生存
研究纳入77例接受曲奥舒凡/氟达拉滨/塞替派预处理的高危重型β地中海贫血移植患者,用LC-MS/MS测血浆曲奥舒凡及活性代谢物S,S-EBDM并建模。曲奥舒凡暴露≥1,660 mg•h/L与1年无地贫生存(TFS)改善显著相关(97% vs 81%,P=0.02),且未随暴露增加观察到方案相关毒性。
要点
- 曲奥舒凡暴露≥1,660 mg•h/L与1年TFS显著改善相关(97% vs 81%,P=0.02)
- 暴露<1,660 mg•h/L是1年TFS不良的独立预测因素(HR=3.23,95%CI 1.12-9.34,P=0.03)
- GSTA1*B变异基因型亦为1年TFS不良独立预测因素(HR=3.75,95%CI 1.04-13.47,P=0.04)
核心结论
- 曲奥舒凡暴露较低增加移植排斥和早期移植相关死亡风险,从而影响无地贫生存。
- 鉴于未观察到随曲奥舒凡暴露增加而出现方案相关毒性,基于治疗药物监测(TDM)的剂量调整可能可行且有益。
研究设计与样本
- 在77例重型β地中海贫血患者中评估曲奥舒凡及其活性代谢物S,S-EBDM的剂量-暴露-反应关系。
- 使用经验证的液相色谱-串联质谱法测定血浆曲奥舒凡/S,S-EBDM水平,并用nlmixr2估计药代动力学参数。
- 评估曲奥舒凡和S,S-EBDM暴露及GSTA1/NQO1多态性对移植排斥、方案相关毒性、嵌合状态、1年总生存(OS)和无地贫生存(TFS)的影响。
主要发现
- 发生移植排斥的患者曲奥舒凡暴露低于未发生排斥者(1,655 vs. 2,037 mg•h/L,P=0.07)。
- 药效学建模确定治疗切点:曲奥舒凡暴露≥1,660 mg•h/L与更好的1年TFS显著相关(97% vs. 81%,P=0.02)。
- 曲奥舒凡暴露≥1,660 mg•h/L与1年OS有改善趋势(90% vs. 69%,P=0.07)。
- 校正已知移植前危险因素的多变量分析显示,曲奥舒凡暴露<1,660 mg•h/L(HR=3.23;95%CI=1.12-9.34;P=0.03)和GSTA1*B变异基因型(HR=3.75;95%CI=1.04-13.47;P=0.04)是1年TFS不良的独立预测因素。
关键数值与推荐
- 曲奥舒凡暴露切点:≥1,660 mg•h/L与更好的1年TFS相关(97% vs. 81%,P=0.02)。
- 曲奥舒凡暴露<1,660 mg•h/L预测1年TFS不良(HR=3.23;95%CI=1.12-9.34;P=0.03)。
- GSTA1*B变异基因型预测1年TFS不良(HR=3.75;95%CI=1.04-13.47;P=0.04)。
临床怎么用
- 对接受曲奥舒凡预处理的高危重型β地中海贫血移植患者,可考虑开展TDM以评估曲奥舒凡暴露。
- 若曲奥舒凡暴露低于1,660 mg•h/L,基于TDM的剂量调整可能有助于改善1年TFS。
- GSTA1*B变异基因型携带者可能需更关注暴露不足风险,但原文未给出该情景下的具体剂量调整方案。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A toxicity-reduced conditioning regimen with treosulfan, fludarabine, and thiotepa in patients with high-risk β-thalassemia major has significantly improved hematopoietic stem cell transplantation (HCT) outcomes. However, complications resulting from regimen-related toxicities (RRTs), mixed chimerism, and graft rejection remain a challenge. We evaluated the dose-exposure-response relationship of treosulfan and its active metabolite S, S-EBDM, in a uniform cohort of patients with β-thalassemia major to identify whether therapeutic drug monitoring (TDM) and dose adjustment of treosulfan is feasible. Plasma treosulfan/S, S-EBDM levels were measured in 77 patients using a validated liquid chromatography with tandem mass spectrometry method, and the pharmacokinetic parameters were estimated using nlmixr2. The influence of treosulfan and S, S-EBDM exposure, and GSTA1/NQO1 polymorphisms on graft rejection, RRTs, chimerism status, and 1-year overall survival (OS), and thalassemia-free survival (TFS) were assessed. We observed that treosulfan exposure was lower in patients with graft rejection than those without (1,655 vs. 2,037 mg•h/L, P = 0.07). Pharmacodynamic modeling analysis to identify therapeutic cutoff revealed that treosulfan exposure ≥1,660 mg•hour/L was significantly associated with better 1-year TFS (97% vs. 81%, P = 0.02) and a trend to better 1-year OS (90% vs. 69%, P = 0.07). Further, multivariate analysis adjusting for known pre-HCT risk factors also revealed treosulfan exposure <1,660 mg•h/L (hazard ratio (HR) = 3.23; 95% confidence interval (CI) = 1.12-9.34; P = 0.03) and GSTA1*B variant genotype (HR = 3.75; 95% CI = 1.04-13.47; P = 0.04) to be independent predictors for inferior 1-year TFS. We conclude that lower treosulfan exposure increases the risk of graft rejection and early transplant-related mortality affecting TFS. As no RRTs were observed with increasing treosulfan exposure, TDM-based dose adjustment could be feasible and beneficial.
引用
- Pai AA, Mohanan E, Panetta JC, et al. Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation. Clin Pharmacol Ther. 2023. PMID: 37846495. doi:10.1002/cpt.3078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。